dr. agarwal on the safety of cabozantinib/atezolizumab in mcrpc
Published 4 years ago • 189 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
1:54
dr. agarwal on developing biomarkers of response to cabozantinib/atezolizumab in mcrpc
-
1:13
dr. agarwal on data with cabozantinib/atezolizumab in mcrpc
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
12:41
cabozantinib in combination with atezolizumab in patients with mcrpc
-
8:38
cabozantinib plus atezolizumab for patients with metastatic castration-resistant prostate cancer
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
3:32
disease control with cabozantinib plus atezolizumab in crpc - medpage today
-
0:51
dr. pal on the rationale for adding cabozantinib to atezolizumab in prostate cancer
-
2:05
dr. agarwal on cohort 6 results from the cosmic-021 trial in mcrpc
-
2:13
dr. agarwal on the cosmic-021 trial design in castration-resistant prostate cancer
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
0:47
tom beer, md on the data presented at asco gu20 investigating atezolizumab and cabozantinib in mcrpc
-
1:50
dr. agarwal on pfs2 data from the titan trial in mcspc
-
1:32
dr. agarwal on treatment for newly diagnosed prostate cancer
-
1:32
bradley mcgregor, md, shares presented data investigating atezolizumab and cabozantinib in mcrpc
-
1:53
contact-2: cabozantinib and atezolizumab in mcrpc
-
1:37
dr. agarwal on drug development in metastatic castration-sensitive prostate cancer
-
5:04
cabozantinib with atezolizumab for mcrpc
-
0:51
rana mckay, md, elaborates on presented data investigating atezolizumab and cabozantinib in mcrpc